Hypercholesterolemia Treatment Market to Grow with a CAGR of 15.69% through 2028
Rising advancements in pharmaceutical research is
expected to drive the Global Hypercholesterolemia Treatment Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Hypercholesterolemia
Treatment Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Hypercholesterolemia
Treatment Market stood at USD 9.76 billion in 2022 and is anticipated to grow
with a CAGR of 7.16% in the forecast period, 2024-2028. Hypercholesterolemia,
characterized by elevated levels of cholesterol in the blood, is a significant
risk factor for cardiovascular diseases, including heart attacks and strokes.
As awareness about the adverse effects of high cholesterol spreads, the global
hypercholesterolemia treatment market is experiencing substantial growth.
One of the
primary drivers fueling the growth of the hypercholesterolemia treatment market
is the increasing prevalence of the condition worldwide. Sedentary lifestyles,
poor dietary habits, and genetic predisposition are contributing to the rise in
hypercholesterolemia cases. With more individuals being diagnosed with high
cholesterol levels, there is a growing demand for effective treatment options
to manage the condition and reduce the risk of cardiovascular diseases.
The global population is aging rapidly, and older
individuals are more prone to hypercholesterolemia. As people age, their bodies
may become less efficient at regulating cholesterol levels. This demographic
shift is a significant driver of the hypercholesterolemia treatment market, as
it leads to a higher number of patients seeking medical intervention to manage
their cholesterol levels. Advancements in medical knowledge and public health
campaigns have led to greater awareness of the dangers of high cholesterol.
Routine cholesterol screening and health check-ups have become more prevalent,
ensuring early diagnosis and treatment. This heightened awareness is
encouraging individuals to proactively manage their cholesterol levels, thus
boosting the demand for cholesterol-lowering medications and interventions. The
pharmaceutical industry is playing a crucial role in driving the
hypercholesterolemia treatment market forward. While statins have long been the
standard treatment for high cholesterol, ongoing research and development
efforts are leading to the discovery of novel cholesterol-lowering drugs and
therapies. Notably, PCSK9 inhibitors have emerged as a promising class of
medications, offering an alternative to statins for patients who may not
tolerate or respond well to traditional treatments. Advances in genetic testing
have enabled healthcare providers to offer more personalized treatment options
for hypercholesterolemia patients. Genetic testing can identify individuals
with specific genetic mutations that contribute to high cholesterol levels.
This information allows healthcare professionals to tailor treatment plans to
the individual's unique genetic profile, improving treatment efficacy and
patient outcomes.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Hypercholesterolemia Treatment Market.”
The Global Hypercholesterolemia Treatment Market
is segmented into disease type, treatment type, end user, regional
distribution, and company.
Based on application, the Global Hypercholesterolemia
Treatment Market is segmented into Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid
Sequestrants, Niacin, Bempedoic Acid, Others. Based on the Treatment Type, the
Statins segment emerged as the dominant player in the global market for Global
Hypercholesterolemia Treatment market in 2022. This is due to their proven
effectiveness in lowering LDL (low-density lipoprotein) cholesterol levels,
which is a primary target in managing hypercholesterolemia. Numerous large-scale
clinical trials and studies have demonstrated that statins can significantly
reduce the risk of cardiovascular events, such as heart attacks and strokes, in
individuals with hypercholesterolemia. This robust body of evidence has
solidified statins as a first-line treatment option for managing high
cholesterol levels and preventing cardiovascular diseases. Furthermore, statins are generally well-tolerated by the majority
of patients. While they may have some potential side effects, such as muscle
pain or liver enzyme abnormalities, these adverse reactions are relatively rare
and can often be managed with appropriate monitoring and adjustments to the
treatment plan. The overall safety profile of statins has contributed to their
widespread acceptance and use among healthcare providers and patients alike.
The convenience of statin therapy also plays a role in
their popularity. Statins are typically administered orally in the form of a
daily pill, making them easy to incorporate into a patient's daily routine.
This simplicity of administration fosters better patient adherence to treatment
plans, which is essential for achieving and maintaining optimal cholesterol
control..
Based on treatment type, the Global Hypercholesterolemia
Treatment Market is segmented into Genetic
Hypercholesterolemia, Acquired Hypercholesterolemia. Based on the
Disease Type, the acquired Hypercholesterolemia segment emerged as the dominant
player in the global market for Global Hypercholesterolemia Treatment in 2022.
Acquired Hypercholesterolemia is more prevalent in the general population
compared to Genetic Hypercholesterolemia. Acquired Hypercholesterolemia is
typically associated with lifestyle factors, such as poor diet, lack of
exercise, and obesity, which are increasingly common in modern societies. As a
result, a larger portion of the global population is affected by acquired forms
of hypercholesterolemia. Acquired Hypercholesterolemia is often related to
modifiable risk factors, which means that lifestyle changes can have a
significant impact on cholesterol levels. This awareness of the link between
lifestyle choices and cholesterol levels has led to a greater emphasis on
cholesterol management in healthcare and public health initiatives, further
boosting the market for treatment options.
North America emerged as the dominant player in the
global Hypercholesterolemia Treatment market in 2022, holding the largest
market share. This is on account of several key factors such as advanced
healthcare infrastructure, Strong Research and Development Ecosystem and high
regulatory acceptance. North America has one of the highest rates of
hypercholesterolemia in the world, with a significant portion of the population
experiencing elevated cholesterol levels. This high prevalence drives the
demand for hypercholesterolemia treatment options, making it a prominent market
in the region.
Major companies operating in Global Hypercholesterolemia
Treatment Market are:
- Amgen Inc
- Amryt Pharma plc
- AstraZeneca Plc.
- Regeneron Pharmaceuticals, Inc.
- Novartis Pharmaceuticals Corporation
- Teva Pharmaceutical Industries Ltd.
- Cipher Pharmaceuticals Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Limited.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global Hypercholesterolemia Treatment market
is being driven by the increasing awareness of the link between high
cholesterol levels and cardiovascular diseases among both healthcare professionals
and the general population Technological advancements in healthcare are
contributing to the growth of the hypercholesterolemia treatment market.
Innovative diagnostic tools and monitoring devices allow for more accurate and
convenient assessment of cholesterol levels. Beyond medications,
non-pharmacological approaches are gaining traction in the hypercholesterolemia
treatment market. Lifestyle modifications, including dietary changes and
increased physical activity, play a critical role in managing cholesterol
levels. As healthcare providers emphasize the importance of these
interventions, patients are becoming more proactive in adopting healthier
lifestyles, reducing their reliance on medications. ” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Hypercholesterolemia Treatment Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Disease Type (Genetic
Hypercholesterolemia, Acquired Hypercholesterolemia), By Treatment Type
(Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin,
Bempedoic Acid, Others), By End User (Hospitals, Specialty Cardiac Centers,
Others) By Region and Competition”, has evaluated the future growth potential of Global Hypercholesterolemia Treatment Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Hypercholesterolemia Treatment Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com